RET and non-small cell lung carcinoma: Further analysis of RET fusion gene-positive NSCLC patients who received treatment showed no heterogeneity among this literature (I2 < 50%, P > 0.1) and then merged ORR from this literature with a fixed effect model to obtain Effect Size (ES) directly.